Background: An emerging problem in the treatment of breast cancer is the increasing
Introduction
Metastasis, the spreading of primary tumours to secondary sites, is responsible for 90 % of deaths from cancer and is a leading cause of morbidity in cancer patients (1) . The incidence of breast cancer patients developing brain metastases is increasing, particularly for those with tumours that are human epidermal growth factor 2 (HER2) positive or triple negative (TN; lacking HER2, progesterone and oestrogen receptor) (2, 3) . Most breast cancer brain metastases occur in the frontal lobe, with cerebellum and parietal lobe also being common sites (4) . The majority are characterised as parenchymal brain metastasis, with 10-20 % occurring as leptomeningeal metastasis (5) . Treatment options are mainly limited to whole brain radiation, in some cases neurosurgery, and survival is poor (6, 7) . Furthermore, patients with metastatic brain tumours present with neurological symptoms including cognitive impairment and epileptic seizures (8, 9) , and this can have a significant impact on quality of life. However, the pathophysiological mechanisms underlying the cause of neurocognitive impairment and tumour-associated epilepsy are poorly understood (10) (11) (12) .
Thus, there is an urgent need to better understand the mechanisms regulating seeding and expansion of brain metastases and their neurological sequelae in order to develop new effective therapies.
As is the case with primary tumours, the heterogeneous microenvironment is thought to play a key role in progression of metastatic disease (13) . In the context of the neural niche, the heterotypic contributions of a range of cell types has been identified, including microglia.
Microglia are the resident innate immune (macrophage) population in the brain and play a key role in neuroinflammatory processes. At steady state, microglia undertake a surveillance role, becoming "activated" following neuronal injury or infection (14) . Microglial activation drives the neuroinflammatory responses that underpin neuronal loss and dysfunction in neurodegeneration, affective disorders, stroke and brain tumours (15) (16) (17) (18) . Under normal physiological conditions in vivo, microglia adopt a highly mobile ramified morphology, constantly scanning the brain parenchyma for injury to neuronal circuitry. Upon detection of a lesion, activated microglia rapidly undergo targeted migration to the injury site where they orchestrate an inflammatory response (19) . Activated microglia are the main immune population clustering around brain metastases in mouse models and patient brain tissue (20) .
The involvement of microglia in progression of metastases is complex and dependent on programming by the local brain tumour microenvironment (18). Microglia interact with metastatic breast cancer cells in a heterogeneous fashion in mouse models, adopting multiple morphological states related to diverse functional contributions to tumour progression (20) . The spectrum of activated microglial phenotypes in brain tumours ranges from "classical" M1 proinflammatory cells capable of releasing proinflammatory cytokines and eliciting a T cell response, to "alternative" M2 anti-inflammatory cells which promote tumour growth, angiogenesis and invasion (21) (22) (23) (24) (25) . Thus, targeting the anti-inflammatory microglial population (26-28), and/or enhancing the activity of the proinflammatory population (29) , may provide a new treatment approach for brain metastases. However, better models are required to improve understanding of the functional activity of microglia in the microenvironment around brain tumour cells.
Intravital two-photon imaging represents a useful tool for studying cellular activity in the microenvironment of tumours in three dimensions and over time (30) . Using this technique, it is possible to visualise tissue structures at cellular resolution in order to understand mechanisms underlying cell-cell interactions and invasion. Intravital imaging approaches using orthotopic breast tumour models have provided important insights into the mechanisms underlying migration and invasion as well as improving understanding of tumour heterogeneity (31) (32) (33) (34) . In the context of brain tumours, intravital imaging has been used to visualise glioma proliferation and invasion, as well as response to anti-tumour therapies (35) . Intravital imaging has also been employed to study microglial activation (14, 36) . However, the approach has not been previously used to directly study the interaction between breast cancer cells and microglia in the brain metastatic niche. In the present study, we sought to address this gap by developing a model to study breast tumour-microglial interactions using intravital imaging combined with ex vivo electrophysiology. Using this approach, it was possible to visualise microglial activation and accumulation, cortical disorganisation and aberrant spontaneous electrical activity around the lesion site.
Materials and Methods

Cell culture
MDA-MB-231 cells were maintained in Dulbecco's modified eagle medium (DMEM) supplemented with 5 % FBS and 4 mM L-glutamine (37) . The cells were stably transduced with recombinant lentivirus for DsRed (gift from M. Lorger, University of Leeds). Cells were confirmed as mycoplasma-free using the DAPI method and their molecular identity was confirmed by short tandem repeat analysis.
Animals
Female heterozygous Cx3cr1
GFP/+ mice on a C57BL/6 (B6) background (obtained from the The installation of a cranial imaging window was based on procedures described previously (39) . Mice (8-17 weeks old; n = 23) were anaesthetised using isoflurane and the head was stabilised in a stereotaxic frame (Kopf Instruments). Cerebral oedema was treated perioperatively with dexamethasone (2 µg/g body weight; intramuscular injection). Post-surgical inflammation was treated peri-operatively and at 24 h intervals for 3 days followed by 48 h intervals for 2 weeks after surgery with carprofen (5 µg/g body weight; subcutaneous injection) and buprenorphine (0.1 µg/g body weight; subcutaneous injection). A small (3 mm diameter) craniotomy was performed on the left parietal bone above the posterior parietal cortex (centred 2.5 mm posterior to Bregma, 2 mm lateral to midline). In some animals,
MDA-MB-231-DsRed cells (10 4 suspended in 20 % v/v Matrigel in saline) were placed in a single drop on the exposed area using a pipette. A 4 mm diameter round No. 1 glass coverslip (Menzel-Gläser) was then placed onto the surgical area, mounted onto the surrounding skull using Vetbond tissue adhesive and sealed in place with dental cement. A small 4 mm x 8 mm titanium plate was attached to the skull using tissue adhesive as an aid for future stabilisation of the head during imaging. Animals were allowed to recover for 5 days before imaging. Weight and body condition were monitored at regular intervals following surgery. Mice were re-grouped following recovery from surgery and were maintained for varying durations up to 1 month following surgery to allow for serial imaging.
Microscope set-up
We used a Zeiss LSM 780 multiphoton fitted to an AxioObserver Z1 inverted microscope and coupled to a Coherent Chameleon Ultra Ti-Sapphire 2-photon laser for this study with 
Intravital imaging
Mice were anaesthetised for restraint using ketamine (100 µg/g body weight) and xylazine (10 µg/g body weight) prior to imaging and placed on their ventral side on the heated microscope stage. The head was stabilised with an in-house custom-made holder to minimise motion artefacts. The light-tight box was pre-warmed to 37 ˚C and was maintained at this temperature for the duration of the imaging session (typically less than 1 h). GFP and DsRed were visualised using two-photon excitation at 920 nm and emission detected via a 500-550 nm band pass filter for GFP and 550 nm long pass filter for DsRed. Images were acquired sequentially and saved for offline processing using Zeiss Zen2 software. The laser power used was up to 15 mW post-objective, dependent on experiment.
Electrophysiology
Coronal slices (450 µm thick) were prepared from the region of the brain under the imaging window, and the contralateral equivalent, at the end of the intravital imaging period. Slices were maintained in an interface chamber at 34 
Immunohistochemistry and confocal microscopy
For tissue preparation and immunohistochemistry mice underwent terminal anaesthesia and perfusion fixation with 4 % paraformaldehyde. Brains (or slices, following termination of electrophysiological experiments) were placed in fixative at 4 ˚C for >48 h and were then washed and sectioned at 20-60 µm. Control mammary tumour and naïve spleen sections were from tissue collected as part of other studies (37) . The following primary antibodies were used as described previously (40) and saved for offline processing using Zeiss Zen2 software.
Image processing and Sholl analysis
Images were imported into the Fiji distribution of ImageJ for processing using the LSM Toolbox plugin. Brightness and contrast were adjusted using the Fiji "auto" function. Imaging depth (µm) was determined relative to that of superficial-most image for each acquisition session. Sholl analysis (41, 42) was performed on imported images as follows: First, arborisation paths on individual microglia (≤ 10 cells/image) were traced using the Simple Neurite Tracer plugin. Next, trace profiles were processed using the Sholl analysis plugin.
For each cell, the number of processes intersecting concentric radii, centred on the nucleus, was recorded at 2 µm intervals and averaged to produce a Sholl plot (41) . In addition, the maximum number of intersections per radius, maximum branch length (largest radius intersecting a branch), number of primary branches originating from the soma, and
Schoenen ramification index (ratio of maximum number of intersections per radius and number of primary branches) were calculated (42, 43) . The number of direct interactions between tumour cells and microglia (where one cell visibly touches another) was counted and divided by the number of tumour cells for a given field of view (44).
Statistical analysis
Data are presented as mean and SEM unless stated otherwise. Statistical analysis was performed using GraphPad Prism 7. Distribution was evaluated using D'Agostino-Pearson normality test. Statistical significance was determined with Mann-Whitney tests for pairwise comparisons and ANOVA followed by Sidak's tests or Kruskal-Wallis followed by Dunn's tests for multiple comparisons, as appropriate. Results were considered significant at P < 0.05.
Results
Validation of intravital multiphoton imaging method
It was necessary to purpose-adapt our two-photon Zeiss LSM 780 microscope with an objective inverter to permit intracranial imaging. We therefore first tested the effect of the customized InverterScope on imaging performance. We confirmed that there was minimal loss of 488 nm and 920 nm excitation power exiting a Plan Apochromat 20x/0.8 objective with the InverterScope in place (Supplementary Figure 1A) . There was also no impact on evenness of illumination across the field (data not shown). Using a standard fluorescent sample there was only a 15 % loss in emission at the internal detectors after 488 nm excitation and a 7 % loss in emission at the non-descanned detectors after 920 nm excitation compared to without the InverterScope (P < 0.001; Supplementary Figure 1B , C).
Given that the modified InverterScope only resulted in minimal (7 %) loss of detected emission, we next used the experimental setup to image GFP-expressing microglia in
Cx3cr1
GFP/+ mice. In the initial pilot study and technique development, animals were killed prior to window implantation and imaging ( Figure 1A ). We evaluated implantation of the optical window on the parietal bone, close to the lambdoid and sagittal sutures, as the best method for examining cellular morphology in situ in the outer cortex, taking into account the potential need for repeated imaging of the same animal. This approach enabled us to detect GFP-expressing microglia in Cx3cr1 GFP/+ mice up to 250 µm below the window using a laser power of 6 mW (as measured at the objective) without significant loss of resolution ( Figure   1Bi -iii). By increasing the laser power to 10 mW, we were able to image deeper, to depths of However, the maximum branch length (maximum radius intersecting a branch) and Schoenen ramification index were unchanged across the range of imaging depths tested (P = 0.11 and 0.43, respectively; n = 10 microglia/imaging depth; Figure 1D , E). Together, these data suggest that, using the InverterScope, it is possible to reliably detect arborisations in ramified microglia at imaging depths up to 350 µm.
Microglia are highly ramified at steady state in vivo
In order to study the ramification of microglia in steady state, we next imaged GFPexpressing microglia in live anaesthetised Cx3cr1 GFP/+ mice, after implantation of the optical window ( Figure 2A ). As with the post mortem imaging, we were able to visualise GFPexpressing microglia in Cx3cr1 GFP/+ mice to depths up to 350 µm, maintaining acceptable resolution ( Figure 2B ). There was some minor loss of image quality compared to post mortem imaging likely as a result of pulse pressure artefacts. Second harmonic generation (SHG) imaging revealed that collagen signal was largely absent in the cortical parenchyma (data not shown), consistent with previous reports (35) . Quantification of microglial arborisations using Sholl analysis revealed a typical branching pattern, similar to that calculated for post mortem images ( Figure 2C ). In addition, the maximum branch length was unchanged across the range of imaging depths tested in vivo (P = 0.14; n ≥ 10 microglia/imaging depth; Figure 2D ). Similarly, the Schoenen ramification index was not significantly different across the same range of imaging depths (P = 0.36; n ≥ 10 microglia/imaging depth; Figure 2E ). Importantly, the maximum number of intersections per radius, maximum branch length, and Schoenen ramification index were unchanged in the in vivo imaged animals compared to post mortem imaged animals (Table 1) , consistent with any reduction in image quality in vivo not precluding detection or measurement of processes. In summary, these data suggest that visualisation of GFP-expressing microglia in anaesthetised live animals permits broadly similar measurement of microglial arborisation to post mortem imaging.
Microglia interact with metastatic breast cancer cells
A growing body of evidence indicates that microglia promote tumour progression (20 Figure 3A ).
Using this approach, we were able to visualise invasion of tumour cells into the cortical parenchyma, together with recruitment of microglia to the lesion site at 5-and 7-days post implantation ( Figure 3B ). Consistent with this, we observed microglia surrounding and directly interacting with tumour cells (Figure 3B , arrowheads). These interactions were evident across all animals studied (additional examples are in Figure 3C ). The number of microglial interactions per breast cancer cell significantly increased between 5-and 7-days post implantation (P < 0.001; n = 8 fields of view/time point; Figure 3D ). In addition, the density of GFP-positive cells was significantly higher in fields of view containing tumour cells compared to animals in which no tumour cells had been implanted (P < 0.01; n ≥ 5 fields of view/condition; Figure 3E ). Sholl analysis of microglial arborisations revealed that the presence of tumour cells notably reduced the number of branches compared to control animals ( Figure 3F) . Similarly, the maximum branch length and Schoenen ramification index were significantly reduced in the presence of cancer cells (P < 0.01 for both; n ≥ 20 microglia/condition; Figure 3G , H). Importantly, implantation of Matrigel alone without tumour cells had no effect on microglial morphology Supplementary Figure 2) . Together, these data suggest that implantation of metastatic breast cancer cells induces activation and accumulation of GFP-expressing microglia.
Persistent alteration of tissue architecture and electrical activity following tumour cell implantation
The accumulation of microglia to the lesion site, which started from 5 days, was maintained at 9-and 13-days post implantation ( Figure 4A-C) . In particular, there was notable accumulation of GFP-positive cells at the periphery of the lesion ( Figure 4A, arrows) .
Interestingly, however, we were no longer able to detect DsRed-positive tumour cells at 9
and 13 days, suggesting that the microglial-induced immune response was capable of clearing the tumour cells from the lesion site ( Figure 4B , C). In agreement with this observation, ex vivo confocal imaging of tissue sections at the end of the experiment revealed that although some DsRed-expressing tumour cells were still present superficially at the pia mater, none were detectable deeper into the tissue ( Figure 5A , B, arrowheads).
Similarly, sections stained with an anti-human nuclear antigen antibody showed an absence of tumour cells at the lesion site ( Figure 6 ). However, we were able to detect punctate acellular DsRed signal adjacent to, or within some GFP-expressing cells, consistent with the possibility that the microglia had destroyed and engulfed some of the tumour cells ( Figure   5A -C, arrows). In addition to microglia, CX3CR1 is also expressed on macrophages, certain subtypes of T cells and natural killer cells (38, 47, 48) , raising the possibility that some of the GFP-positive population at the lesion site may constitute other cell types. The microgliaspecific marker TMEM119 (49) was expressed on ramified microglia in control brain parenchyma and there was also strong staining at the lesion site ( Figure 7A, B) . There was some limited infiltration of CD45 hi GFP − leukocytes at the lesion site compared to normal brain parenchyma ( Figure 8A, B) . However, the majority of GFP + cells were CD45 low or − , consistent with these cells being microglia ( Figure 8B ). Together, these data suggest that the GFP + cells at the lesion are predominantly microglia. In addition, the lack of CD45 hi cells suggests that there is minimal infiltration of other immune cells in response to the xenograft.
Given the striking observation of significant and persistent microglial accumulation to the tumour site, we postulated that the lesion may disrupt normal cortical electrophysiological function. We therefore next evaluated spontaneous electrical activity in coronal tissue slices under the imaging window and on the contralateral side to the implantation site.
Spontaneously-occurring local field potential spike events were observed in slices taken from the region of the brains underlying the tumour cell implantation sites in all cases.
Events were only seen in superficial layers, particularly layer 2 (L2) and never seen in deep layers ( Figure 9A ) or in any layer contralateral to the inoculation site. Mean spike amplitude was 98 ± 6.0 µV (n = 138 events from slices from 2 mice) with 5/138 outliers where amplitude was >0.5 mV. Field spike durations were highly variable and non-normally distributed ( Figure 9B ). Three modal peak halfwidths were seen at 48, 111 and 215 ms.
Morphology of the field spikes was highly dependent on recording electrode position relative to the lesion ( Figure 9C ). Within the lesion itself bursts of multi-unit activity occurred with no concurrent field spike. This pattern was reversed peri-annularly around the lesion wall in L2, with overt field spikes seen with no concurrent multi-unit activity. In summary, the imaging and electrophysiological data reveal that in this model there is a significant and persistent microglial response to the location of metastatic breast cancer cells, and although this is capable of removing some of the tumour cells, there remains significant disruption to normal electrical activity within and adjacent to the lesion site.
Discussion
In this study, in mice expressing GFP under control of the endogenous Cx3cr1 promoter, we were able to visualise microglial behaviour in the cortex at a depth of up to 350 µm using system that is easy to manipulate (14, 30, 36) .
Primary and metastatic brain tumours can have a range of neurological consequences such as headaches, mild cognitive impairment, and epileptic seizures (12) . This aspect of the disease burden in the brain has a significant impact on quality of life and is difficult to treat as the mechanistic basis is poorly understood (10) (11) (12) . Several mechanisms have been proposed to explain the presentation of tumour-associated epilepsy, including disrupted glutamate homeostasis, altered ion channel expression, altered network activity, and inflammation (52-55). We found aberrant spontaneously-occurring local field potential spike events local to the tumour. In addition, the activity pattern differed within the lesion compared to peri-annularly around the lesion wall, suggesting that changes within the tumour and peritumoral tissue may differentially mediate altered electrical activity. The altered excitability and electrical signatures observed here resemble interictal-like epileptic wave forms that have been associated with poor cognitive performance and have been seen in electroencephalograms (EEGs) of patients presenting with epilepsy (56) , suggesting that our model may recapitulate early stages of cortical disorganisation that could subsequently lead to tumour-associated epilepsy. Furthermore, the data raise the possibility that peritumoral microglial activation and accumulation may play a critical role in local tissue changes leading to aberrant cortical activity.
Conclusions
The results presented here show that it is possible to visualise the microglial response to metastatic breast tumour cells using intravital imaging. Using this approach, we demonstrate that activated microglia accumulate at the lesion site, giving rise to peritumoral cortical 
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